Unveiling Conflicts of Interest in Medical Research: Why Transparency Matters
"A recent case highlights the critical need for accurate financial disclosure in medical publications, ensuring trust and reliability in healthcare advancements."
In the realm of medical research, transparency isn't just a buzzword; it's the bedrock upon which trust and progress are built. When researchers fail to disclose potential conflicts of interest, the integrity of their findings—and the treatments that stem from them—can be called into question. A recent incident involving a paper published in the JAMA Otolaryngology-Head & Neck Surgery journal serves as a stark reminder of why these disclosures matter.
The issue came to light when Dr. José Baselga, a prominent figure in the field of oncology, acknowledged a failure to report potential conflicts of interest in several articles he had published. This admission underscores the complexities and potential pitfalls of maintaining objectivity when financial ties to pharmaceutical companies and other entities are involved.
This article aims to delve into the specifics of this case, exploring the implications of undisclosed conflicts of interest and highlighting the measures necessary to ensure transparency and accountability in medical research. By understanding these issues, healthcare professionals, patients, and the public can better navigate the ever-evolving landscape of medical advancements.
Industry Funding and Trust
Clinical study results for drugs and medical devices can affect medical practice and the treatments offered to patients, while companies that make those products increasingly conduct or fund the research. The Cochrane source describes this growing role of industry sponsorship. The World Health Organization’s CIOMS guidance says sponsors’ financial assistance should not be provided directly to review committees or tied to decisions on specific protocols. The ICMJE emphasizes that complete author disclosures support transparency and trust in the scientific process.
Disclosure as a Management Strategy
Conflict-of-interest policies and practices have evolved over more than four decades alongside increasing industry relationships in medical education, research, and practice. The NCBI overview notes that debate has intensified over how to balance the risks and expected benefits of these relationships. A study on disclosure in clinical research argues that understanding real-world decision-making and practices around telling potential participants about financial interests is necessary to assess disclosure’s successes and limitations. This points to a limitation: policy or disclosure requirements alone do not establish how disclosure works in practice.
The Failure to Disclose: A Closer Look
The original issue stemmed from a paper published in JAMA Otolaryngology-Head & Neck Surgery, as well as related articles in the JAMA Network journals between 2015 and 2018. The article in question, "Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial," initially reported no conflicts of interest. However, this was later found to be inaccurate.
- Roche/Genentech: Nonfinancial support and reimbursement for travel.
- Aura Biosciences: Serving on the board of directors (2013-2017); Fees and stock ownership.
- Infinity Pharmaceuticals: Serving on the board of directors (2013-2017); Fees and stock ownership.
- PMV Pharma Biotechnologies: Serving on the scientific advisory board (2014-present); Fees and stock ownership.
- Juno Therapeutics (acquired by Celgene): Serving on the scientific advisory board (2014-2017); Fees and stock ownership.
- Grail: Serving as a member or chair of the scientific advisory board (2016-2018); Fees and stock ownership.
- Varian Medical Systems: Serving on the board of directors (2017-2018); Fees and stock ownership.
- Bristol-Myers Squibb: Serving on the board of directors (March to September 2018); Fees and stock ownership.
- Seragon (acquired by Roche): Serving on the scientific advisory board (2013-2014); Fees and stock ownership.
- ApoGen Biotechnologies: Stock ownership; Serving on the scientific advisory board (2014-present).
- Foghorn Therapeutics: Serving on the board (2017-present); Fees and stock ownership.
- Tango (formerly Synthetic Lethal): Cofounder, receiving fees from, and stock ownership (2016-present).
- Northern Biologics (formerly Mosaic Biomedicals): Serving on the scientific advisory board (2013-present); Fees and stock ownership.
- Novartis and Eli Lilly: Receiving consulting and travel fees.
- Venthera: Cofounder.
- Serving as investigator on a patent licensed to Memorial Sloan Kettering for use of phosphoinositide 3-kinase inhibitors.
- Serving as investigator for patents pending assignment to Memorial Sloan Kettering for combination therapy using PDK1 and PI3K inhibitors.
Guideline Authors’ Industry Payments
A cross-sectional study examined 270 US physician authors of 20 clinical practice guidelines. It found that 101 authors (37.4%) disclosed industry-related financial conflicts of interest, while 199 (73.7%) were found to have received industry payments when payments disclosed through Open Payments were also counted. These figures distinguish authors’ disclosures from payments identified through the database. Separately, a 2025 article describes research into policy mechanisms addressing funding bias and author conflicts as a policy priority for public trust, patient safety, and research integrity.
Evidence Requires Caution
A systematic review of conflicts of interest and favorable recommendations cautions that its evidence should be interpreted carefully: 15 of 21 studies dealt inadequately with confounding, and all effect estimates in the primary analyses lacked statistical precision. A pilot study likewise says its finding about funding source and trial outcomes may reflect either a true absence of association or limitations inherent in the pilot design. These sources therefore do not support treating every observed association—or lack of one—as conclusive. The HHS definition frames a conflict as a situation in which financial or personal considerations have the potential to compromise or bias professional judgment, rather than proof that bias occurred.
Financial and Non-Financial Interests
An NIH guide is intended to help clinical researchers, people involved in statistical analysis, IRB members, and consultants identify and avoid real or apparent financial and non-financial conflicts of interest. A 2025 literature review says financial conflicts have an extensive research literature, while publications on non-financial conflicts are comparatively rare. It also notes disagreements about the importance of non-financial interests in research and publication. Together, these sources indicate that guidance addresses both kinds of interests, but the literature on them is not equally developed.
Correcting the Record and Moving Forward
In response to the failure to disclose, Dr. Baselga requested that the original article be corrected online to include a complete disclosure statement. This step is essential for rectifying the record and ensuring that readers have access to accurate information. Additionally, the JAMA Otolaryngology-Head & Neck Surgery journal published a letter detailing the missing conflict of interest disclosures and providing a link to the corrected article. Such measures are vital for maintaining trust in the scientific community and promoting responsible research practices.
Tracking Conflicts in Oncology Trials
A study published in July 2025 set out to systematically analyze the prevalence and trends of conflicts between clinical trial investigators and biopharmaceutical companies in oncology trials published in the Journal of Clinical Oncology (JCO) over the previous 15 years. Its stated aim also included demonstrating the utility of large language models (LLMs). The source describes the study’s goals, not its findings, so it does not establish what trends the analysis identified. A separate 2026 chapter reports that financial conflicts between doctor-researchers and sponsoring pharmaceutical companies are widespread and says studies show an association with outcomes favoring company interests.
Institutional Ties and Oversight
A 2025 source describes institutional conflicts of interest as arising when an interest held by an individual or an institution affects the research process or its outcome, raising concerns about transparency and integrity. A JAMA article reports that financial relationships among industry, scientific investigators, and academic institutions are widespread and can influence biomedical research in important ways. It also reports substantial variation in how academic institutions and peer-reviewed journals manage financial conflicts. These sources highlight that oversight concerns extend beyond individual researchers to institutional relationships and inconsistent management practices.
Researchers’ Experiences and Patient Disclosure
A 2020 qualitative interview study set out to characterize trial researchers’ experiences of whether and how conflicts of interest had unduly influenced trials they had worked on, the strategies used to minimize potential influence, and their views on conflicts more generally. The source describes the study’s objectives but does not provide its interview findings in the supplied material. An AMA Journal of Ethics case describes Dr A, a principal investigator studying a vagal nerve stimulator (VNS), whose professional duty to conduct research objectively conflicts with a personal interest in favorable study outcomes. The case asks what investigators should tell patient-subjects about industry relationships.